ALTAMIRA THERAPEUTICS LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.48 USD | -9.20% |
|
-18.68% | -57.47% |
| Apr. 10 | Transcript : Altamira Therapeutics Ltd., 2023 Earnings Call, Apr 10, 2024 | |
| Apr. 10 | Altamira Therapeutics Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 3.06M 3.37M |
|---|---|---|---|---|---|
| Net income 2024 * | - | Net income 2025 * | - | EV / Sales 2024 * | - |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | 10 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.11% |
More Fundamentals
* Assessed data
More news
Latest transcript on Altamira Therapeutics Ltd.
More press releases
| 1 day | -9.20% | ||
| 1 week | -18.68% | ||
| Current month | -28.50% | ||
| 1 month | -12.43% | ||
| 3 months | -38.33% | ||
| 6 months | -55.95% | ||
| Current year | -57.47% |
1 week
1.42
1.88
1 month
1.423.49
Current year
1.423.60
1 year
1.4228.40
3 years
1.421 832.00
5 years
1.422 640.00
10 years
1.42636 800.00
| Managers | Title | Age | Since |
|---|---|---|---|
Thomas Meyer
CEO | Chief Executive Officer | 56 | 03-03-31 |
Marcel Gremaud
DFI | Director of Finance/CFO | 66 | 21-10-31 |
Covadonga Pañeda
COO | Chief Operating Officer | 51 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Alain Munoz
BRD | Director/Board Member | 75 | 18-02-28 |
Mats Blom
BRD | Director/Board Member | 59 | 17-03-31 |
Thomas Meyer
CEO | Chief Executive Officer | 56 | 03-03-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-18 | 1.5 | +1.35% | 24,812 |
| 24-04-17 | 1.48 | -9.20% | 90,008 |
| 24-04-16 | 1.63 | -1.81% | 56,575 |
| 24-04-15 | 1.66 | -9.29% | 120,702 |
| 24-04-12 | 1.83 | +0.55% | 41,161 |
End-of-day quote Nasdaq, April 16, 2024
More quotes
Altamira Therapeutics Ltd. is a Bermuda-based company engaged in developing ribonucleic acid (RNA)-based therapeutics for extrahepatic targets (OligoPhore/SemaPhore delivery platforms). The Company has two flagship short interfering (siRNA) programs in preclinical development beyond in vivo proof of concept: AM-401 for KRAS driven cancer and AM-411 for rheumatoid arthritis. The delivery platform is also suited for messenger RNA (mRNA) and other types of RNA therapeutics and is focused to be leveraged via out-licensing to pharma or biotech companies. The therapeutic objective for AM-401 is to slow down KRAS driven tumor cell growth and proliferation or to stop it altogether by delivering siRNA specifically inside tumor cells for gene knock down. AM-411 is a polyplex nanoparticle delivering siRNA to inflamed tissues to target the NF-kB signaling pathway, a critical regulator of immune and inflammatory responses. Like AM-401, the drug product is based on its OligoPhore technology.
Calendar
2024-08-14
- Q2 2024 Earnings Release (Projected)
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -57.47% | 3.36M | |
| -3.30% | 102B | |
| +1.79% | 96.07B | |
| -1.78% | 21.66B | |
| -18.35% | 20.77B | |
| -8.58% | 18.53B | |
| -40.31% | 16.91B | |
| -26.84% | 13.79B | |
| +0.59% | 13.33B | |
| +20.86% | 10.94B |
- Stock Market
- Equities
- CYTO Stock
